Lexaria Bioscience Corp (LXX.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 08/31
| 08-2024 | 05-2024 | 02-2024 | 11-2023 | 08-2023 | |
| Cash Flows From Operating Activities | |||||
| Depreciation Amortization | -8 | 39 | 16 | 29 | 71 |
| Accounts receivable | 46 | 125 | 187 | -408 | -3 |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | N/A | -784 |
| Other Working Capital | 174 | 76 | -9 | -135 | -715 |
| Other Operating Activity | -2,104 | -1,506 | -813 | -668 | -191 |
| Operating Cash Flow | $-1,892 | $-1,266 | $-620 | $-1,182 | $-1,622 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -43 | 0 | 0 | 0 | 0 |
| Purchase Sale Intangibles | -27 | -22 | -57 | -40 | -68 |
| Other Investing Activity | -27 | 0 | -57 | -40 | -68 |
| Investing Cash Flow | $-70 | $-22 | $-57 | $-40 | $-68 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 0 | 0 | 2,961 | 1,248 | -122 |
| Other Financing Activity | 0 | 5,043 | 492 | 572 | 0 |
| Financing Cash Flow | $0 | $5,043 | $3,453 | $1,819 | $-122 |
| Exchange Rate Effect | 2 | -1 | -25 | 4 | N/A |
| Beginning Cash Position | 8,459 | 4,705 | 1,954 | 1,352 | 3,164 |
| End Cash Position | 6,500 | 8,459 | 4,705 | 1,954 | 1,352 |
| Net Cash Flow | $-1,961 | $3,755 | $2,776 | $598 | $-1,812 |
| Free Cash Flow | |||||
| Operating Cash Flow | -1,892 | -1,266 | -620 | -1,182 | -1,622 |
| Capital Expenditure | -70 | -22 | -57 | -40 | -68 |
| Free Cash Flow | -1,961 | -1,288 | -677 | -1,222 | -1,690 |